A randomized open‐label trial detected no significant between‐group difference in short‐term symptom response, while a completer analysis found differences in weight change over 12 months.
The first approved norepinephrine, dopamine, and serotonin reuptake inhibitor for ADHD demonstrated symptom improvements as early as week 1 in phase 3 trials.
National survey findings suggest many US adults report making health decisions based on social media despite widespread concerns about the accuracy of health information shared to the platforms.